ISEE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ISEE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
IVERIC bio's gross profit for the three months ended in Mar. 2023 was $0.00 Mil. IVERIC bio's gross profit for the trailing twelve months (TTM) ended in Mar. 2023 was $0.00 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. IVERIC bio's gross profit for the three months ended in Mar. 2023 was $0.00 Mil. IVERIC bio's Revenue for the three months ended in Mar. 2023 was $0.00 Mil. Therefore, IVERIC bio's Gross Margin % for the quarter that ended in Mar. 2023 was N/A%.
IVERIC bio had a gross margin of N/A% for the quarter that ended in Mar. 2023 => No sustainable competitive advantage
The historical data trend for IVERIC bio's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IVERIC bio Annual Data | |||||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
Gross Profit | Get a 7-Day Free Trial | - | - | - | - | - |
IVERIC bio Quarterly Data | ||||||||||||||||||||
Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | |
Gross Profit | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, IVERIC bio's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, IVERIC bio's Gross Profit distribution charts can be found below:
* The bar in red indicates where IVERIC bio's Gross Profit falls into.
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
IVERIC bio's Gross Profit for the fiscal year that ended in Dec. 2022 is calculated as
Gross Profit (A: Dec. 2022 ) | = | Revenue | - | Cost of Goods Sold |
= | 0 | - | 0 | |
= | 0.00 |
IVERIC bio's Gross Profit for the quarter that ended in Mar. 2023 is calculated as
Gross Profit (Q: Mar. 2023 ) | = | Revenue | - | Cost of Goods Sold |
= | 0 | - | 0 | |
= | 0.00 |
Gross Profit for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)
IVERIC bio's Gross Margin % for the quarter that ended in Mar. 2023 is calculated as
Gross Margin % (Q: Mar. 2023 ) | = | Gross Profit (Q: Mar. 2023 ) | / | Revenue (Q: Mar. 2023 ) |
= | (Revenue - Cost of Goods Sold) | / | Revenue | |
= | 0.00 | / | 0 | |
= | N/A % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
IVERIC bio (NAS:ISEE) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
IVERIC bio had a gross margin of N/A% for the quarter that ended in Mar. 2023 => No sustainable competitive advantage
Thank you for viewing the detailed overview of IVERIC bio's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Keith Westby | officer: SVP & COO | ONE UNIVERSITY SQUARE DRIVE, SUITE 280, PRINCETON NJ 08540 |
David Francis Carroll | officer: SVP, CFO and Treasurer | ONE UNIVERSITY SQUARE DRIVE, SUITE 280, PRINCETON NJ 08540 |
Glenn Sblendorio | director | 3 TIMES SQAURE, 12TH FLOOR, NEW YORK NY 10036 |
Christopher Paul Simms | officer: Senior Vice President, CCO | FIVE PENN PLAZA SUITE 2372, NEW YORK NY 10001 |
Anthony S Gibney | officer: EVP, Chief Business Officer | C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511 |
Calvin W. Roberts | director | 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005 |
Christine Ann Miller | director | 5 PENN PLAZA, SUITE 2372, NEW YORK NY 10001 |
Pravin Dugel | officer: EVP, Chief Strategy & Business | C/O AERPIO PHARMACEUTICALS, INC., 9987 CARVER ROAD, CINCINNATI OH 45242 |
David R Guyer | director, officer: Chief Executive Officer | ONE PENN PLAZA, 19TH FLOOR, NEW YORK NY 10119 |
Mark S. Blumenkranz | director | C/O 1LIFE HEALTHCARE, INC., ONE EMBARCADERO CENTER, SUITE 1900, SAN FRANCISCO CA 94111 |
Adrienne L Graves | director | 125 STONE MOUNTAIN CIRCLE, NAPA CA 94558 |
Versant Venture Capital Iv, L.p. | 10 percent owner | ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104 |
Versant Ventures Iv, Llc | 10 percent owner | ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104 |
Versant Side Fund Iv, L.p. | 10 percent owner | ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104 |
Jane Henderson | director | C/O ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142 |
From GuruFocus
By Business Wire Business Wire • 12-20-2022
By sperokesalga sperokesalga • 05-02-2023
By Business Wire Business Wire • 05-01-2023
By Business Wire Business Wire • 05-02-2023
By sperokesalga sperokesalga • 05-01-2023
By PRNewswire PRNewswire • 06-15-2023
By sperokesalga sperokesalga • 05-02-2023
By Business Wire Business Wire • 12-01-2022
By PRNewswire PRNewswire • 05-09-2023
By PRNewswire PRNewswire • 05-01-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.